UBS raises Moderna price target ahead of pipeline catalysts

What happened: UBS and RBC Capital raised their price targets on Moderna (MRNA) to $45, citing upcoming pipeline catalysts. Key drivers include progress on an mRNA-based flu vaccine, expected approval within two months, and strong year-to-date performance (+100%). Moderna's stock price has more than doubled this year, driven by optimism around its pipeline and regulatory progress.

Market impact: Biotechnology and healthcare sectors are affected, with Moderna's peers and investors in immunology stocks taking note. The price target increases reflect a repricing of Moderna's valuation, pushing shares up to $49.06 on July 6, 2026.

What to watch next: Moderna's participation in a conference next week (July 13, 2026) and the potential U.S. approval of a combination COVID-19 and flu vaccine (expected within two months) will be crucial catalysts. Additionally, investors will closely monitor Moderna's Q2 earnings report, scheduled for August 5, 2026.